BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36012610)

  • 1. Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.
    Yang YT; Yuzbasiyan-Gurkan V
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.
    Marley K; Helfand SC; Edris WA; Mata JE; Gitelman AI; Medlock J; Séguin B
    BMC Vet Res; 2013 Jan; 9():15. PubMed ID: 23331343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.
    Poon AC; Inkol JM; Luu AK; Mutsaers AJ
    J Vet Intern Med; 2019 Mar; 33(2):800-811. PubMed ID: 30556178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.
    Skorupski KA; Uhl JM; Szivek A; Allstadt Frazier SD; Rebhun RB; Rodriguez CO
    Vet Comp Oncol; 2016 Mar; 14(1):81-7. PubMed ID: 24118677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
    McMahon MB; Bear MD; Kulp SK; Pennell ML; London CA
    Am J Vet Res; 2010 Jul; 71(7):799-808. PubMed ID: 20594083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
    Inkol JM; Poon AC; Mutsaers AJ
    Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma.
    Chun R; Garrett LD; Henry C; Wall M; Smith A; Azene NM
    J Am Anim Hosp Assoc; 2005; 41(6):382-7. PubMed ID: 16267062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
    Patatsos K; Shekhar TM; Hawkins CJ
    Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance.
    Shahi MH; York D; Gandour-Edwards R; Withers SS; Holt R; Rebhun RB
    PLoS One; 2015; 10(6):e0131006. PubMed ID: 26110620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma.
    Marley K; Helfand SC; Simpson J; Mata JE; Tracewell WG; Brownlee L; Bracha S; Séguin B
    J Exp Clin Cancer Res; 2013 Oct; 32(1):74. PubMed ID: 24422857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canine osteosarcoma: amputation and chemotherapy.
    Berg J
    Vet Clin North Am Small Anim Pract; 1996 Jan; 26(1):111-21. PubMed ID: 8825570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.
    Wolfesberger B; Tonar Z; Gerner W; Skalicky M; Heiduschka G; Egerbacher M; Thalhammer JG; Walter I
    Res Vet Sci; 2010 Feb; 88(1):94-100. PubMed ID: 19665156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of P16 expression in canine appendicular osteosarcoma.
    Murphy BG; Mok MY; York D; Rebhun R; Woolard KD; Hillman C; Dickinson P; Skorupski K
    BMC Vet Res; 2017 Jun; 13(1):189. PubMed ID: 28633676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.
    Selmic LE; Burton JH; Thamm DH; Withrow SJ; Lana SE
    J Vet Intern Med; 2014; 28(2):554-63. PubMed ID: 24512451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
    York D; Withers SS; Watson KD; Seo KW; Rebhun RB
    Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006).
    Bacon NJ; Ehrhart NP; Dernell WS; Lafferty M; Withrow SJ
    J Am Vet Med Assoc; 2008 May; 232(10):1504-10. PubMed ID: 18479240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial.
    Vail DM; Kurzman ID; Glawe PC; O'Brien MG; Chun R; Garrett LD; Obradovich JE; Fred RM; Khanna C; Colbern GT; Working PK
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):131-6. PubMed ID: 12172978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma.
    McMahon M; Mathie T; Stingle N; Romansik E; Vail D; London C
    J Vet Intern Med; 2011; 25(3):511-7. PubMed ID: 21488959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of circulating microRNA-214 and -126 in dogs with appendicular osteosarcoma receiving amputation and chemotherapy.
    Heishima K; Meuten T; Yoshida K; Mori T; Thamm DH
    BMC Vet Res; 2019 Jan; 15(1):39. PubMed ID: 30683101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which dogs with appendicular osteosarcoma benefit most from chemotherapy after surgery? Results from an individual patient data meta-analysis.
    Schmidt AF; Groenwold RH; Amsellem P; Bacon N; Klungel OH; Hoes AW; de Boer A; Kow K; Maritato K; Kirpensteijn J; Nielen M
    Prev Vet Med; 2016 Mar; 125():116-25. PubMed ID: 26796424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.